Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Dr. Gary W. Pace as an Independent Non-Executive Director with immediate effect.
October 23, 2018 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Dr. Gary W. Pace as an Independent Non-Executive Director with immediate effect.
Dr. Gary W. Pace brings more than 40 years of experience in the development and commercialization of advanced life sciences and related technologies, including biotechnology, pharmaceuticals and medical devices. He is a serial entrepreneur and has held senior positions in small to large-scale life sciences ventures and companies in Australia, the USA and Europe. Dr. Pace is currently a director of ResMed (NYSE: RMD), Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Simavita Ltd (ASX: SVA) and Antisense Therapeutics Ltd (ASX: ANP) as well as several private companies.
Dr. Pace has actively contributed to the development and growth of the global Life Sciences and Healthcare industry through honorary university appointments and industry and government committees. He was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was also awarded Director of the Year (corporate governance) by the San Diego Directors Forum.
Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology (MIT) where he was a Fulbright Fellow and General Foods Scholar. He has also held visiting academic positions at the Massachusetts Institute of Technology and the University of New South wales and University of Queensland. He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering.
Dr. Pace commented on his appointment:
“I am excited to join Invitrocue at an important point in the company’s development. Onco-PDOTM has the potential to truly disrupt the way in which physicians determine the treatment plan of their cancer patients based on personalised guidance, ultimately delivering better outcomes for patients. I look forward to working closely with the team to share my experience and provide guidance on developing successful commercialisation strategies.”
Commenting on the appointment, Dr. Steven Fang, Chief Executive Director, Invitrocue, said:
“Dr. Pace brings not only impressive commercial experience from international healthcare companies but he is also a well-respected researcher who has written and co-written more than 30 research papers, reviews and patents. We look forward to his guidance and contributions as we continue with the international roll-out of our Onco-PDOTM Personalised Oncology testing services, and in broadening our menu of validated tumour types, changing the way cancers are being treated one patient at a time.”
-ENDS-
For more information contact:
Martin D. Bach, VP Operations
T: +65 6460 0497
About Invitrocue
Invitrocue is a leading healthcare bio-analytic solutions provider including in-vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics any human organ for using in the field drug testing. In 2016, the company applied its work and know how in liver disease to the field of oncology. Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
Invitrocue’s technology originated from Singapore’s Agency for Science, Technology and Research (A*STAR) and Massachusetts Institute of Technology (MIT). Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com
